沙格雷酯改善2型糖尿病患者胰岛素抵抗及胰岛素敏感性的临床观察

Clinical observation on effects of sarpogrelate on insulin resistance and insulin sensitivity in patients with type 2 diabetics

目的探讨沙格雷酯对2型糖尿病患者胰岛素抵抗及胰岛素敏感性下降改善。方法2型糖尿病合并大血管病变患者60例，分为对照组（单纯降糖）及治疗组（沙格雷酯联合降糖药治疗），各30例，分别于4、12和24周监测血糖和胰岛素相关指标，以及24周内血糖波动情况。结果治疗4、12和24周后，治疗组FPG、胰岛素抵抗指数低于对照组，胰岛素敏感性指数较高于对照组（P〈0．01）。结论采用沙格雷酯联合治疗，患者胰岛素抵抗明显下降，胰岛素敏感性增强。

Objective To investigate the effects of sarpogrelate on insulin resistance and insulin sensitivity in patients with type 2 diabetics. Methods A total of 60 type 2 diabetic patients with macroangiopathy were randomly divided into control group （ n = 30, with admistration of hypoglycemic agent ） and treatment group （n = 30, with admistration of hypoglycemic agent and sarpogrelate）. The indexes related to plasma glucose and insulin were observed at 4, 12 and 24 weeks after administration. The fasting plasma glucose （FPG） and postprandial blood glucose were observed dynamically in 24 weeks follow up. Results At 4, 12 and 24 weeks after administration, the FPG and insulin resistance index were lower in treatment group than those in control group, and insulin sensitivity index was higher in treatment group than that in control group, with a significant difference （P 〈 0.01 ）. Conclusion Combined treatment of hypoglycemic agent and sarpogrelate can reduce the insulin resistance and increase insulin sensitivity in patients with type 2 diabetic